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Radiotherapy with external beam radiation or brachytherapy is an established therapeutic modality for prostate cancer.
Approximately 30% of patients with localised prostate cancer relapse at the irradiated site. Secondary effects of ionising radiation (IR),
for example, bowel and bladder complications, are common. Thus, the search for biological response modifiers that could potentiate
the therapeutic effects of radiation and limit the occurrence of serious side effects is an important task in prostate cancer therapy.
1a,25-Dihydroxyvitamin D3 (calcitriol), the active metabolite of vitamin D, and its analogues are under investigation for the treatment
of several malignancies including prostate cancer. Here, we report that 1a,25-dihydroxyvitamin D3 and its less calcaemic analogue 19-
nor-1a,25-(OH)2D2 (Zemplar
s) act synergistically with IR to inhibit the growth of the human prostate cancer cells in vitro.1 a,25-
dihydroxyvitamin D3 potentiated IR-induced apoptosis of LNCaP cells, and nanomolar doses of 1a,25-dihydroxyvitamin D3 and 19-
nor-1a,25-(OH)2D2 showed synergistic inhibition of growth of LNCaP cells at radiobiologically relevant doses of IR (1–2Gy). At
higher doses of IR, the combination of 1a,25-dihydroxyvitamin D3 and IR or 19-nor-1a,25-(OH)2D2 and IR resulted in moderate
antagonism. The synergistic effect at radiobiologically relevant doses of radiation suggests that a combination of 1a,25-
dihydroxyvitamin D3 or 19-nor-1a,25-(OH)2D2 with IR could permit a reduction in the dose of radiation given clinically and thus
potentially reduce treatment-related morbidity.
British Journal of Cancer (2003) 89, 746–753. doi:10.1038/sj.bjc.6601161 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: Zemplar; vitamin D; radiosensitizer; synergistic
                                                                                                     
Adenocarcinoma of the prostate is the most commonly diagnosed
nonskin cancer and the second leading cause of cancer death in
men in the United States (Keely and Gomella, 1998; Garnik and
Fair, 1998; Jemal et al, 2003). Most men will present with clinically
localised disease but a significant minority will present with locally
advanced disease. In patients with locally advanced disease (T3–4)
the rates of local control with radiation therapy alone have been
reported to range from 60 to 77% (Shipley et al, 1995). In a recent
Phase III trial in men with locally advanced prostate cancer, the
rate of local regional control in the radiation-alone arm was 83%
(Bolla et al, 2002). Since this trial did not require prostate biopsies
following treatment, the rate of loco-regional control is likely an
overestimate.
It is clear that in men with locally advanced disease, optimal
local control with radiation therapy has not been achieved. There
is some evidence that higher radiation doses may improve local
control, but higher doses lead to increased morbidity, especially
rectal bleeding (Pollack et al, 2002). Whether used for cure or
palliation, side effects of RT are common and include adverse
effects on urinary, bowel and sexual function (Hamilton et al,
2001). Evidence also exists suggesting that the cells that survive the
initial RT are the ones most likely to repopulate the irradiated area
and metastasise (Fuks et al, 1991). Thus, agents or methods that
could potentiate the effects of ionising radiation would be very
desirable. Ideally, such agents would permit a reduction in the
dose of radiation administered and thereby, a potential reduction
in the incidence and/or severity of side effects.
The steroid hormone 1a,25-dihydroxyvitamin D3
(1a,25(OH)2D3), also known as calcitriol, the active metabolite of
vitamin D, and its synthetic analogues are currently under
intensive investigation for several malignancies, including prostate
cancer (Campbell and Koeffler, 1997). Based on the observation
that the descriptive epidemiology of prostate cancer resembles that
of vitamin D insufficiency, Schwartz and Hulka (1990) proposed
that vitamin D maintained the differentiated phenotype of prostate
cells and that low levels of vitamin D increase the risk for prostate
cancer. Many subsequent epidemiologic (Ahonen et al, 2000;
Luscombe et al, 2001) and laboratory studies (Feldman et al, 2000)
have supported this hypothesis. For example, 1a,25(OH)2D3 and its Received 3 March 2003; revised 22 May 2003; accepted 4 June 2003
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sanalogues exhibit significant growth-inhibitory, proapoptotic,
anti-invasive and antimetastatic effects on prostate tumour cell
lines in vitro and in vivo (Miller et al, 1992; Peehl et al, 1994;
Schwartz et al, 1995, 1997; Skowronski et al, 1995; Campbell et al,
1997; Asou et al, 1998; Lokeshwar et al, 1999; Blutt et al, 2000; Seol
et al, 2000). These studies support the potential use of
1a,25(OH)2D3 and its analogues as therapeutic agents for prostate
cancer (reviewed in Blutt and Weigel, 1999).
The principal limitation of 1,25(OH)2D3 administration is the
risk of hypercalcaemia. Consequently, many synthetic analogues of
1,25(OH)2D3 have been developed with the goal of developing
analogues that exhibit similar or enhanced growth-inhibitory and
antimetastatic properties with reduced calcaemic effects (Schwartz
and Hulka, 1990) (see also Hansen et al (2001) for a review).
Prominent vitamin D analogues include EB1089 (Seocalcitol),
which is currently in Phase III trials in Europe for hepatocellular
carcinoma, 1-a-vitamin D2 and 19-nor-1a,25-(OH)2D2 (Zemplar),
a 1,25(OH)2D3-analogue that is FDA-approved for the treatment of
secondary hyperparathyroidism. Laboratory studies have demon-
strated that the antiproliferative effects of 19-nor-1a,25-(OH)2D2
on prostate cancer cells are indistinguishable from those of
1a,25(OH)2D3 (Chen et al, 2000).
In addition to its use as monotherapy, calcitriol and analogues
may prove useful in conjunction with other treatment modalities,
notably, ionising radiation. Observations that support combining
1,25(OH)2D3 with ionising radiation include the following: (a) both
IR and 1,25(OH)2D3 induce apoptosis in prostate carcinoma cells
by apparently distinct pathways (Welsh et al, 1995; Billis et al,
1998; James et al, 1998; Pirianov et al, 1999; Ding and Fisher, 2001;
McGuire et al, 2001; Sheard, 2001; Liu et al, 2002); (b) other agents
that induce cellular differentiation, for example, phenylacetate,
platelet-derived growth factor and retinoic acid, are known to
enhance the cytotoxic effects of IR (Bill et al, 1992b; Miller et al,
1997; Hoffmann et al, 1999); (c) EB 1089 has been shown to
enhance the radiation sensitivity of breast carcinoma cells
(Sundaram and Gewirtz, 1999). These findings strongly suggest
that 1,25(OH)2D3 may enhance the cytotoxic effects of IR on
prostate cancer cells. In this report, we investigated the effects of
combined treatments of 1a,25(OH)2D3 and 19-nor-1a,25-(OH)2D2
with IR on the apoptosis and growth of the human prostate cancer
cell line LNCaP, as well as on the growth of a human primary
prostatic cell strain obtained from patients who had undergone
radical prostatectomy.
MATERIALS AND METHODS
Reagents
1a,25(OH)2D3 was purchased from Biomol, Inc. (Plymouth Meet-
ing, PA, USA). 19-nor-1a,25(OH)2D2 was a generous gift from
Abbott Laboratories (Chicago, IL, USA). Both were dissolved in
100% ethanol and kept at  801C until use. Final concentration of
EtOH in the media was 0.1% (VV
 1).
Cell culture
The LNCaP cell line was purchased from the American Type
Culture Collection (Rockville, MD, USA) and maintained in RPMI
1640 supplemented with 10% foetal calf serum (FCS). Primary
human epithelial cell cultures from histologically normal prostatic
peripheral zones or prostate cancer were obtained from radical
prostatectomies performed at Wake Forest University School of
Medicine as previously described (Peehl and Stamey, 1986; Peehl
et al, 1988; Barreto et al, 2000). Briefly, a small piece of tissue from
each specimen is removed and minced. The tissue is digested with
collagenase overnight. To remove the collagenase and the majority
of the stromal cells, the tissue is rinsed and centrifuged. The
collagenase-digested tissue is inoculated into a 60-mm tissue
culture dish coated with collagen type I (Collagen Corporation,
Palo Alto, CA, USA) and grown in medium PFMR-4A supple-
mented with growth factors and hormones (Peehl et al, 1988).
Previous studies have demonstrated that prostatic stromal cells do
not grow in the serum-free conditions used in this study, yet these
conditions maintain the growth and differentiation of prostatic
epithelial cells (Peehl and Stamey, 1986; Peehl et al, 1988). The cells
that grew out from the tissue were aliquoted and stored in liquid
nitrogen. The histology of each specimen was verified by inking
and fixing the prostate after dissection and serially sectioning the
marked area. The histology of sections immediately adjacent to the
area of the dissection was reviewed and classified as histologically
normal or cancerous by a trained pathologist. The frozen aliquots
were thawed to produce secondary cultures, which were grown in
medium MCDB 105 (Sigma, St Louis, MO, USA) supplemented
with growth factors and hormones (Peehl and Stamey, 1986).
Irradiation
LNCaP cells were plated in 24-well plates at densities of 5000 cells
per well. Primary cells were plated onto 35mm dishes at a cell
density of 1 10
4dish
 1. At the end of preincubation with
1a,25(OH)2D3 or 19-nor-1a,25(OH)2D2, cells were irradiated in a
137Caesium irradiator (Shepherd and Associates) at a dose rate of
472radmin
 1. Following IR, the cells were returned to the
incubator and were allowed to grow for another 12–14 days,
before assessment of viability as described below.
Apoptosis assay
Cells were plated in 60mm plastic dishes at a density of 2 10
5
cells per plate 24h prior to treatment. Following treatments,
determination of the number of apoptotic cells was assayed. Cells
with apoptotic morphology are determined by incubating cells
with Bisbenzimide (Hoechst 33342) dye and propidium iodide
(PI), both at a concentration of 2mgml
 1 for 10min. Cells with
apoptotic morphology (fragmented nuclei and PI-positive cells)
were counted in each of four fields randomly selected in the dish
and expressed as a ratio to total number of cells. Both attached and
floating cells were counted. The results represent the average of
three independent experiments (7s.e.m.).
Cellular proliferation assays
Two types of cellular proliferation assays were employed. For
assessing human prostatic cell strain proliferation, trypan-blue
exclusion was used as a marker of viable cells 9–12 days after
treatments. The WFU10Ca strain cells were plated onto 35mm
dishes and treated with 1a,25(OH)2D3 or ethanol, h EtOH). After
24h later, cells were irradiated as described above. To assess the
effects of 1a,25(OH)2D3 or 19-nor-1a,25(OH)2D2 on LNCaP cell
proliferation, 5000 cells were plated onto 24-well plates and treated
with 1a,25(OH)2D3 or 19-nor-1a,25(OH)2D2. Cells were irradiated
24h later. After 10–12 days, cell viability was assessed by the MTT
assay according to the manufacturer’s protocol. A volume of 200ml
aliquots from each reaction was transferred into a 96-well plate
and absorbance values were measured with an automated plate
reader (Molecular Dynamics, Sunnyvale, CA, USA). Each experi-
ment was performed in triplicate.
Isobologram analysis of combination treatments
The isobologram analysis was performed using the CalcuSyn
software (Biosoft, Cambridge, UK). The analysis is based on the
median-effect principle and the median effect equation by Chou
(1974): fa/fu¼(D/Dm)
m, where D is the dose of the drug; Dm is the
median-effect dose; fa is the fraction affected by the dose, fu the
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sfraction unaffected by the dose, fu¼1 fa; and m is an exponent
signifying the sigmoidy (shape) of the dose–effect plot.
The Combination Index (CI) (Table 1) for multiple drug
combinations is calculated based on the equation and plot by
Chou and Talalay:
CI ¼
X n
j¼1
ðfaÞj
ðfuÞj
where n¼number of drugs.
In the simplest form, a CIo1, ¼1 and 41 indicate synergism,
additive effect and antagonism, respectively. Chou and Talalay
(1984) also recommend a scale based on the value of CI and using
symbols ranging from þþþþþ for very strong agonism to
      for very strong antagonism. The CI values calculated
from our experiments follow this scale.
RESULTS
To test whether 1a,25(OH)2D3 affects the apoptotic response of
LNCaP cells to IR, cells were treated with vehicle (0.1% EtOH) or
with 100nM 1a,25(OH)2D3. After 48h, the cells were either
irradiated with 4Gy IR or were mock-irradiated. Cells with
apoptotic morphology (fragmented nuclei and PI-positive cells)
were counted. Figure 1 shows photographs from representative
populations at  100 and  250 magnifications. Treatment with
1a,25(OH)2D3 or IR alone did not induce substantial apoptosis of
LNCaP cells, as is evident from the absence of cells with
fragmented and/or condensed nuclei in this representative field.
However, pretreatment with 1a,25(OH)2D3 for 48h followed by IR
resulted in a significant increase in the percentage of cells with
apoptotic morphology (indicated by white arrows). Figure 1B
shows the cumulative results obtained by counting cells with
apoptotic vs normal morphology in four randomly selected fields
from three independent experiments. Although 1a,25(OH)2D3 and
IR induced only modest levels of apoptosis (13 and 17%,
respectively) compared to basal levels (5%), pretreatment of
LNCaP cells with 1a,25(OH)2D3 for 48h prior to IR resulted in 48%
apoptosis. These results indicate that pretreatment of LNCaP cells
with 1a,25(OH)2D3 prior to IR sensitises these cells to IR-induced
apoptosis.
While apoptotic assays can be useful in determining the short-
term effects of agents on cells, they may not reflect the long-term
effects of these agents on cellular proliferation. To investigate the
effects of 1a,25(OH)2D3 and 19-nor-1a,25(OH)2D2 on long-term
proliferation of prostate cells, we treated LNCaP cells with different
doses of the hormones and IR, and assessed cell viability 8 days
later using the MTT assay. As seen in Figure 2A and B, both agents
induced a dose-dependent decrease in the survival of LNCaP cells.
An isobologram analysis of the data revealed that at lower doses of
drug and IR, a significant but modest synergistic effect is observed
(Figure 3A and B). At increased concentrations of drug (100nM)
and IR (4Gy) (point 4 in isobolograms), the two agents exert
antagonistic effects on proliferation. These results suggest that the
combination of low nanomolar doses of 1a,25(OH)2D3 or 19-nor-
1a,25(OH)2D2 with low doses of IR may have beneficial effects in
vivo for the treatment of prostate cancer.
We also wanted to test the effects of 1a,25(OH)2D3 on the
response of primary prostate tumour cells to IR. Previously, it was
shown that 1a,25(OH)2D3 inhibited the growth of primary
prostatic cells in a dose-dependent manner (Peehl et al, 1994;
Barreto et al, 2000). We first tested a range of doses of
1a,25(OH)2D3 for its ability to inhibit cell growth in a variety of
normal and cancer-derived cell clones (data not shown). A dose of
1n M had only a minimal effect on the growth of all strains tested.
We next tested the effects of combined treatments of 1nM
1a,25(OH)2D3 with increasing doses of IR. As shown in Figure 4
for a cancer-derived strain (WFU10Ca), IR treatments caused a
dose-dependent decrease in cell proliferation. Pretreatment of
these cells with 1nM 1a,25(OH)2D3 caused a significant reduction
in cell proliferation at 1 and 2Gy, but it failed to further increase
the inhibitory effect of 1a,25(OH)2D3 at a dose of 4Gy. Therefore,
similar to the results obtained with LNCaP cells, radiation and
1a,25(OH)2D3 act synergistically to inhibit cell proliferation at low
doses of drug and IR.
A desired effect of radiation sensitisers/enhancers is a differ-
ential cytotoxic profile between tumour and normal cells. Thus, we
also investigated the effects of the combined treatments of
1a,25(OH)2D3 and IR on the proliferative capacity of normal
prostatic stromal cells, which are of fibroblastic origin and thus
provide a good model for normal tissue injury. These cells were
pretreated with various doses of 1a,25(OH)2D3 for 48h, after which
they were irradiated with doses of 1 and 2Gy. Table 2 shows the
results of selected treatment combinations for these primary
normal cells and the corresponding data for LNCaP cells. These
data show that with the exception of the combined dose of 1nM
1a,25(OH)2D3 and 2Gy, which produced the highest levels of
synergy for both the normal and LNCaP cells, the stromal cells
were substantially more resistant to combined treatments than
LNCaP cells. Furthermore, even at the synergistic combination of
1n M 1a,25(OH)2D3 and 2Gy, the overall inhibitory effect on
Table 1 Combination Index (CI) values and Dose Reduction Index (DRI) for combined treatments of vitamin D and IR (A) or Zemplar and IR (B)
Mutually nonexclusive CI for experimental values Dose Reduction Index (DRI)
IR (Gy) fa CI (point #) Degree of syn./antag. Vitamin D IR
(A) Vitamin D (nM)x
0.1 1 0.34 0.85 (1) + 3.77 2.18
1 2 0.60 0.57 (2) +++ 9.46 2.36
10 4 0.74 0.76 (3) ++ 6.70 1.89
100 4 0.75 2.43 (4)     0.79 1.96
(B) Zemplar (nM) Zemplar
0.1 1 0.45 1.27 (1)    2.08 1.88
1 2 0.79 0.45 (2) +++ 10.81 3.05
10 4 0.89 0.54 (3) +++ 7.85 2.75
100 4 0.86 4.22 (4)      0.39 2.23
CI values for each combination treatment at doses shown on the left were calculated with the CalCuSyn software as described in Materials and Methods. CI values correspond to
points shown in the isobolograms depicted in Figure 3. The DRI for each drug:IR combination is a measure of how much (-fold) the dose of a drug or agent (e.g. IR), in synergistic
combination may be reduced at a given effect level compared with the dose of each drug alone. The DRI is another mathematical interpretation of the CI, and CI¼1/(DRI)1+1/
(DRI)2. +++++, very strong agonism; ––––– very strong antagonism.
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sstromal cell proliferation was lower than that observed for LnCaP
cells, as evident by the affected fraction (Fa) values (0.4 vs 0.6,
respectively).
DISCUSSION
1a,25(OH)2D3 and its analogues have shown synergistic activities
with a variety of chemotherapeutic agents, including cisplatin and
doxorubicin. In breast cancer cells, 1a,25(OH)2D3 and EB1089
were reported to enhance the effects of ionising radiation, although
the lack of isobologram analysis in that study does not permit an
assessment of a synergistic or additive effect (Sundaram and
Gewirtz, 1999). Here, we demonstrate for the first time that in a
prostate tumour cell line and primary tumour cells, 1a,25(OH)2D3
and 19-nor-1a,25(OH)2D2 act synergistically with IR to inhibit the
growth of these tumour cells.
The synergistic effects of these agents with IR are manifested as
an increase in apoptotic index of treated LNCaP cells, and as a
decreased proliferation in longer-term assays in LNCaP and
primary prostate cells. However, since the synergistic effect on
apoptosis was observed with high doses of IR and 1a,25(OH)2D3,a
combination that was antagonistic in longer-term assays, our
results suggest that apoptosis is probably not involved in any
synergistic long-term antiproliferative effects of these agents. One
possible explanation for these results is the following: inhibition of
proliferation by 1a,25(OH)2D3 and its analogues and IR involves
multiple mechanisms, of which apoptosis is only one component.
Terminal differentiation (or permanent cell cycle arrest) and
mitotic (necrotic) death due to unrepaired DNA strand breaks also
contribute substantially to decreased proliferation. It is possible
that 1a,25(OH)2D3 and IR induce apoptosis via distinct mechan-
isms and therefore exhibit synergistic activation of apoptosis, but
that differentiation and/or necrosis work by mechanisms that are
mutually inhibited at higher drug or IR doses. This result is not
surprising, since similar drug combinations (e.g., cisplatin and
1a,25(OH)2D3) also appear to produce antagonistic effects at high
doses.
Although short-term apoptotic assays do not always demon-
strate a good correlation with overall cell survival in in vitro
assays, apoptosis may play a role in vivo. For example, increased
apoptosis in a tumour as a result of treatment with a cytotoxic
agent may contribute to reoxygenation of previously hypoxic
tumour cells, and thus contribute to cytotoxicity of subsequent IR
treatments (Brown and Wouters, 1999; 2001). In LNCaP cells, the
increased apoptotic index after a 48h incubation suggests that
pretreatment of cells with 1a,25(OH)2D3 lowers the apoptotic
threshold of the cells to the subsequent stress of IR. A potential
mechanism for this finding involves downregulation of the
antiapoptotic protein bcl-2, which has been reported to occur as
a result of treatment with 1a,25(OH)2D3 or its analogues (Welsh
et al, 1995; Simboli-Campbell et al, 1997; Narvaez et al, 2001).
If an increase in apoptosis does not play a major role in the
long-term antiproliferative synergistic interaction between
1a,25(OH)2D3 and its analogues, what other potential mechanisms
may be involved in this process? First, calcitriol and its analogues
induce cellular differentiation, a process in which a precursor cell
acquires morphological and biochemical characteristics of specia-
lised lineage (Studzinski et al, 1993). In the processes of
tumorigenesis, cells reverse this process and become less
differentiated (i.e., they dedifferentiate). Cells undergoing differ-
entiation appear to be more sensitive to ionising radiation than
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Figure 1 Pretreatment of LNCaP cells with 1a,25(OH)2D3 sensitises
LNCaP cells to IR-induced apoptosis. (A) Photographs depict representa-
tive populations from the different treatment groups at  100 and  250
magnifications. Cells with apoptotic morphology appear with brighter
stained nuclei ( 100 magnification). In the  250 magnification, apoptotic
cells are indicated by white arrows in the 1,25VDþIR treated group. (B)
Cells were treated with ethanol (control) or 100nM 1a,25(OH)2D3 for
48h prior to treatment with 4Gy IR and apoptotic cells were counted 12h
after IR. The apoptotic cells from four randomly selected fields were
counted (between 50 and150cellsfield
 1). Three independent experi-
ments were performed. Error bars represent7s.e. values.
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scells that have a more undifferentiated phenotype. For instance,
using a murine 3T3-T proadipocyte cell line, Bill et al have
demonstrated that although both undifferentiated and differen-
tiated cells sustain similar levels of DNA damage when irradiated,
undifferentiated cells exhibit higher levels of DNA repair (Bill et al,
1992a, b). Similar mechanisms may explain the increased
sensitivity of cells treated with the prodifferentiating agents
phenylacetate and phenylbutyrate (Miller et al, 1997). Indeed,
calcitriol has been shown in earlier studies to potentiate the
cytotoxic effects of chemotherapeutic agents by inducing cell
differentiation (Ravid et al, 1999). Second, treatment of the human
prostate cells LNCaP and PC-3 with calcitriol results in cell cycle
arrest, primarily at the G1/S interphase, while a G2/M arrest has
also been reported (Eisman et al, 1989; Godyn et al, 1994; Zhuang
and Burnstein, 1998). As shown by work with synchronised cell
cultures, with the exception of the M phase of the cell cycle (where
cells in culture are the most radiosensitive), the majority of cell
lines show the greatest sensitivity to ionising radiation in late G1/
early S phase and during the G2/M transition (Nias, 1988), and are
the most radioresistant during early G1 and S phases. Therefore, it
is reasonable to expect that pretreatment of prostate cancer cells
with 1a,25(OH)2D3 and 19-nor-1a,25(OH)2D2 will increase their
sensitivity to IR by inducing the entry of the majority of the cells in
these two radiosensitive phases.
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Figure 2 Dose–response effects of 1a,25(OH)2D3 (A) or 19-nor-
1a,25(OH)2D2 (B) alone, or combined with IR on the growth of LNCaP
prostate tumour cells. Cells were plated in medium and drugs were added
24h later. Cells were irradiated 24h following addition of 1a,25(OH)2D3
or 19-nor-1a,25(OH)2D2 and allowed to grow for an additional 7 days, at
which time MTT assay was performed as described in Materials and
Methods. Optical density (OD) values represent the average of four
readings per experiment. Each experiment was performed three times.
Error bars represent s.e. values.
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Figure 3 Isobologram plots for vitamin D and IR (A) or Zemplar and IR
(B) combinations. Shown are normalised isobolograms indicating the
equipotent combinations of the drugs at IC50 doses. As nonconstant ratios
of drug:IR doses were used, the drug and IR concentrations on the isobol
are normalised by the corresponding IC50 doses. Individual points refer to
the specific dose ratios of combinations of drug:IR, indicated in the legend.
If a combination data point for fa¼0.5 falls on the diagonal, an additive
effect is indicated; on the lower left, synergy is indicated; on the upper right,
antagonism is indicated. For actual CI values and degrees of synergism or
antagonism, see Tables 1 and 2.
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Figure 4 Effects of combined treatments of 1a,25(OH)2D3 and IR on
primary prostate cells. Cells were isolated from patients who underwent
radical prostatectomy at WFU as described in Materials and Methods. Cells
were plated into 35mm dishes and treated with 1nM 1a,25(OH)2D3. After
24h, cells were irradiated in a caesium irradiator with the indicated doses
and returned to 371C for growth for an additional 10–12 days. At the end
of treatment, cells were trypsinised and counted. Control cells received
only 0.1% ethanol. Experiments were performed in triplicate. The example
shown is from the WFU10Ca, a cancer-derived primary strain. Similar
results were obtained with two other cancer-derived and three normal
prostate-derived strains.
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sRegardless of the mechanism(s) of synergy, our data show that
1a,25(OH)2D3 and 19-nor-1a,25(OH)2D2 (which are both currently
in clinical trials for the treatment of advanced prostate cancer)
exhibit significant levels of synergy with one of the most widely
used therapeutic modalities for prostate cancer, IR. Importantly,
this potentiation occurs at low doses of both drug and IR, which
fall well within the range of clinically relevant doses. For example,
radiotherapy protocols for prostate cancer patients routinely
employ multiple daily fractions of IR at 1.5–2Gy per treatment
for a total dose to the prostate between 64 and 72Gy (Perez, 1997).
As shown in our isobolograms, greatest synergism occurs at the IR
doses of 2Gy. Furthermore, the doses of 1a,25(OH)2D3 and 19-nor-
1a,25(OH)2D2 that exhibit synergism are in the low nanomolar
range. Intracellular levels of 1a,25(OH)2D3 in the prostate have not
been characterised. However, it is now clear that these levels likely
exceed by several fold the levels of 1a,25(OH)2D3 in the systemic
circulation (picomolar levels (Platz et al, 2000)). This is because
both normal and cancerous prostate cancer cells express 1-a-
hydroxylase, which enables these cells to convert the prohormone
25-OHD3, which circulates at nanomolar concentrations, into
1a,25(OH)2D3, intraprostatically (Schwartz et al, 1998). Prostate
cells that express 1-a-hydroxylase are growth inhibited by 25-
OHD3 at nanomolar concentrations (Barreto et al, 2000). There-
fore, both 1a,25(OH)2D3 and 19-nor-1a,25(OH)2D2 are capable of
acting synergistically with IR at physiological doses, at least in
vitro. Animal experiments will be required in order to validate
these concepts in vivo.
Another conclusion of our study is that at higher doses of
1a,25(OH)2D3 and 19-nor-1a,25(OH)2D2 and IR, antagonism occurs.
This finding is in agreement with similar studies using
1a,25(OH)2D3, cisplatin and carboplatin (Moffatt et al,1 9 9 9 ) .
Although the mechanism(s) for this antagonistic effect is unknown,
it is well established that the synergy or antagonism between two
drugs with different modes of action is largely dependent upon the
drug concentrations and ratios. If these findings extend to in vivo
models, they would suggest that careful dosage and patient
monitoring must be employed if a combination of 1a,25(OH)2D3
or 19-nor-1a,25(OH)2D2 with IR is administered clinically.
The experiments with the primary cell cultures indicate that
1n M 1a,25(OH)2D3 can also sensitise primary prostatic cells (both
tumour and normal) to IR treatments. This finding supports the
potential use of 1a,25(OH)2D3 and Zemplar as IR-response
modifiers in vivo, since these cell strains retain most of the
morphological and biochemical features of human prostatic tissue.
Conversely, the ability of certain combinations of these agents to
sensitise normal prostatic tissue to the effects of IR raises the
possibility of increased radiation-induced adverse effects (i.e.,
prostatitis) in surrounding normal prostatic tissue. However, the
data also suggest that at least in vitro, combinations of
1a,25(OH)2D3 and IR exist that might preferentially sensitise
tumour but not normal prostate cells. Ultimately, such effective
drug combinations will need to be established experimentally in
either animal tumour models of prostate cancer before these
agents are administered for therapeutic purposes in the clinic.
Finally, it is possible that in a clinical setting, potential damage to
normal tissue might be mitigated by brachytherapy in which
radioactive ‘seeds’ are delivered locally to the tumour tissue, which
would minimise the exposure of surrounding normal tissue to
radiation.
The isobologram analysis and DRI of the effects of these agents
on LNCaP cells also suggest that it may be possible to decrease the
dose of IR and/or 1a,25(OH)2D3 and 19-nor-1a,25(OH)2D2 in
combined modalities, without sacrificing efficacy. This finding has
important clinical implications because the incidence of morbidity
caused by RT increases with radiation dose (Perez, 1997). For
instance, the DRI value of 2.4 for IR in the combination of
1a,25(OH)2D3 (1nM) and IR (2Gy) indicates that to achieve the
same efficacy level in the absence of 1a,25(OH)2D3, one would have
to give 2.4 times higher dose of IR. In other words, the presence of
1a,25(OH)2D3 allows for a 2.4 times lower dose of IR to obtain the
same therapeutic effect. Conversely, the 9.5 DRI value for
1a,25(OH)2D3 indicates that at this combination of doses, the
presence of IR allows for almost a 10-fold decrease in the level of
1a,25(OH)2D3 to achieve the same therapeutic effect. As noted
above, one of the limiting factors of administration of
1a,25(OH)2D3 is hypercalcaemia. Our results show that by
combining the two modalities it may be possible to reduce the
levels of 1a,25(OH)2D3 or19-nor-1a,25(OH)2D2 without a signifi-
cant compromise in efficacy, which would minimise the risk of
hypercalcaemia.
In summary, we have shown that 1a,25(OH)2D3 and its less
calcaemic analogue 19-nor-1a,25(OH)2D2 show synergistic effects
when combined with radiation treatments. Both these drugs are
approved for clinical use and both are presently under clinical
investigation as monotherapy in prostate cancer. These findings
have implications for limiting the disability (e.g., rectal and
bladder injury) induced by radiation therapy. Future studies will
focus on the in vivo interactions between these treatment
modalities (using LNCaP xenograft tumour models) for the
treatment of prostate cancer.
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